Sexual Dysfunction; Treatment

NWHRC Health Center - Sexual Dysfunction, Dec 23, 2005

"Recommendations for estrogen and progesogen use in peri- and postmenopausal women: October 2004 position states of the North American Menopause Society." Menopause (The Journal of NAMS) 2004 11;6:589-600. Available at http://www.menopause .org. Accessed December 9, 2004.

"FDA Plans to Evaluate Results of Women's Health Initiative Study for Estrogen-Alone Therapy." U.S. Food and Drug Administration. "FDA Talk Paper." March 2, 2004. http://www.fda.gov. Accessed December 9, 2004.

"FDA Approves New Labels for Estrogen and Estrogen with Progestin Therapies for Postmenopausal Women Following Review of Women's Health Initiative Data." FDA News/Press Release. January 8, 2003. http://www.fda.gov. Accessed December 9, 2004.

Lacey, James V., et al. "Menopausal Hormone Replacement Therapy and Risk of Ovarian Cancer." JAMA 2002; 288:334-341.368-369.

Grady D, Herrington D, Bittner V, et al, for the HERS Research Group. Heart and estrogen/progestin replacement study follow-up (HERS II): Part 1. Cardiovascular outcomes during 6.8 years of hormone therapy. JAMA 2002;288:49-57.

Hulley S, Furberg C, Barrett-Connor E, et al, for the HERS Research Group. Heart and estrogen/progestin replacement study follow-up (HERS II): Part 2. Non-cardiovascular outcomes during 6.8 years of hormone therapy. JAMA 2002;288:58-66.

Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-333.

"NHLBI Stops Trial of Estrogen Plus Progestin Due to Increased Breast Cancer Risk, Lack of Overall Benefit." National Heart, Lung and Blood Institute. http://www.nhlbi.nih.gov. July 9, 2002. Accessed December 9, 2004.

"Findings from the WHI Postmenopausal Hormone Therapy Trials." Women's Health Initiative, National Heart, Lung and Blood Institute. National Institutes of Health. http://www.nhlbi.nih.gov. Accessed December 9, 2004.

Ricardo Manuel Munarriz, Lily Talakoub, Nancy Lahey, Melissa Gioia, Aleksander Chudnovsky, Elise De, Irwin Goldstein. Boston University, Boston, MA. "Hormone, Sexual Function and Personal Sexual Distress (SDS) Outcomes Following Dehydroepiandrosterone (DHEA) Treatment for Female Sexual Dysfunction (FSD) and Androgen Deficiency Syndrome (ADS)" Poster session presented at the 2001 American Urological Association annual meeting.

Menopause Guidebook: Helping Women Make Informed Healthcare Decisions through Perimenopause and Beyond. North American Menopause Society: May 2003. http://www.menopause.org. Accessed December 9, 2004.

"Androgen." Health Center Topic. National Women's Health Resource Center. http://www.healthywomen.org. Accessed Eecember 9, 2004.

"Androgen Replacement No Panacea for Women's Libido." American College of Obstetricians and Gynecologists. News release. Oct. 31, 2000. http://www.acog.org. Accessed December 9, 2004.

Berman, J, and Berman, L. "Female Sexual Dysfunction: Definitions, Causes & Potential Treatments." Network for Excellence in Women's Sexual Health. http://www.newshe.com. Accessed December 9, 2004.